Recurrent lower limb arterial thrombosis in a patient with heparin-induced thrombocytopenia – Case report
Abstract
Background: Heparin-induced thrombocytopenia (HIT) is an immune-mediated disorder following heparin therapy presenting with thrombocytopenia and associated arterial or/and venous thrombosis (heparin induced thrombocytopenia with thrombosis–HITT). Unrecognised HIT can lead to severe complications like limb amputation and death.
Case report: We report a case of a patient who presented with HIT-associated recurrent lower limb arterial thrombotic occlusions and popliteal venous thrombosis 29 days after coronary bypass graf surgery. The patient underwent urgent thrombectomy of superfcial femoral, popliteal and posterior tibial artery. Because of recurrent thrombotic occlusions of lower limb arteries three surgical revisions were performed. Te platelet count decreased from 124 × 109/l to 53 × 109/l on the fifth day after the first intervention. After clinical suspicion of HIT, heparin was discontinued and fondaparinux was started. Arterial thrombosis did not recur and the patient recovered without consequences.
Conclusions: HIT occurs in 1–3 % of patients after cardiac surgery. Strict following of international guidelines regarding the frequency of platelet count monitoring, assessing probability for HIT and laboratory testing is mandatory in order not to miss the diagnosis of HIT. HIT can manifest clinically several days after the first exposure to heparin. If a patient presents with acute thrombosis and thrombocytopenia, HITT should be suspected. Postoperative HIT is associated with higher morbidity and mortality. Early recognition is crucial to prevent severe complications and death.
Downloads
References
Warkentin TE, Hayward CP, Boshkov LK, Santos AV, Sheppard JA, Bode AP, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84(11):3691–9.
Aster RH. Heparin-Induced Trombocytopenia and Trombosis. New England Journal of Medicine. 1995;332(20):1374–6.
Warkentin TE. Heparin-Induced Trombocytopenia: Diagnosis and Management. Circulation. 2004;110(18):e454-e8.
Warkentin TE, Kelton JG. Temporal Aspects of Heparin-Induced Trombocytopenia. New England Journal of Medicine. 2001;344(17):1286–92.
Kozak M, Dovč-Drnovšek T, Gmeiner Stopar. S heparinom povzročena trombocitopenija – HIT. Zdrav Vestn. 2008;77:239–45.
Maličev E, Kozak M, Rožman P. Evaluation of a flow cytometric assay for the confirmation of heparin-induced thrombocytopenia. International Journal of Laboratory Hematology. 2016;38(3):240–5.
Greinacher A. Heparin-Induced Trombocytopenia. N Engl J Med. 2015;373(19):1883–4.
Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. The Annals of Toracic Surgery. 2003;76(2):638–48.
Matthai WH, Cines DB. Towards a diagnosis of heparin-induced thrombocytopenia after cardiopulmonary bypass. Journal of Trombosis and Haemostasis. 2004;2(11):1879–81.
Lillo-Le Louet A, Boutouyrie P, Alhenc-Gelas M, Le Beller C, Gautier I, Aiach M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. Journal of Trombosis and Haemostasis. 2004;2(11):1882–8.
Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Terapy and Prevention of Trombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141 (Suppl 2):495–530.
Salter BS, Weiner MM, Trinh MA, Heller J, Evans AS, Adams DH, et al. Heparin-Induced Trombocytopenia. Journal of the American College of Cardiology. 2016;67(21):2519–32.
Singer RL, Mannion JD, Bauer TL, Armenti FR, Edie RN. Complications From Heparin-induced Trombocytopenia in Patients Undergoing Cardiopulmonary Bypass. Chest. 1993;104(5):1436–40.
Maličev E, Dovč-Drnovšek T, Rožman P. Serološke in funkcijske preiskave pri diagnosticiranju trombocitopenije, povzročene s heparinom (HIT). Zdrav Vestn 2012;81:149–58.
Assmann A, Boeken U, Feindt P, Schurr P, Akhyari P, Lichtenberg A. Heparin-induced Trombocytopenia Type II afer Cardiac Surgery: Predictors and Outcome. Te Toracic and Cardiovascular Surgeon. 2010;58(08):463–7.
Kerendi F, Tourani VH, Puskas JD, Kilgo PD, Osgood M, Guyton RA, et al. Impact of Heparin-Induced Trombocytopenia on Postoperative Outcomes Afer Cardiac Surgery. The Annals of Toracic Surgery. 2007;84(5):1548–55.
Warkentin TE, Kelton JG. Delayed-Onset Heparin-Induced Trombocytopenia and Trombosis. Annals of Internal Medicine 2001;135(7):502–6.
Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Te American journal of medicine. 1999;106(6):629–35.
Warkentin TE, Kelton JG. Temporal Aspects of Heparin-Induced Trombocytopenia. New England Journal of Medicine 2001;344(17):1286–92.
Szokol JW. Heparin-Induced Trombocytopenia. Seminars in Cardiothoracic and Vascular Anesthesia. 2010;14(1):73–4.
Pouplard C, Regina S, May MA, Gruel Y. Heparin-induced thrombocytopenia: a frequent complication after cardiac surgery. Archive du maladies du coeur et des vaisseaux. 2007;100:563–8.
Walenga JM, Jeske WP, Messmore HL. Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. Journal of Trombosis and Trombolysis 2000;10(1):13-20.
Kreidy R, Hatem J. Acute limb ischemia secondary to heparin-induced thrombocytopenia after cardiac surgery. J Med Liban. 2004;52:175–81.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
